 | Up a level |
Goto, K., Wolf, J., Elamin, Y., Santini, F., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B., Novello, S., Arriola Aperribay, E., Perol, M., Loong, H., Drilon, A., Park, K., Solomon, B. and Zhou, C. (2021). LIBRETTO-431: Selpercatinib in Treatment-Naive Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 16 (3). S. S228 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Johnson, M. L., de langen, A. J., Waterhouse, D. M., Mazieres, J., Dingemans, A-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Okamoto, I., Kim, S-W., Linardou, H., Novello, S., Chen, Y., Solomon, B., Obiozor, C., Wang, Y. and Paz-Ares, L. (2022). Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. Ann. Oncol., 33 (7). S. S1417 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Mazieres, J., Novello, S., De Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Wolf, J., Zeaiter, A., Cardona, A., Balas, B., Karagiannis, T., Chlistalla, M., Smoljanovic, V. and Oh, I. (2017). Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC. J. Thorac. Oncol., 12 (11). S. S1897 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Novello, S., Mazieres, J., Oh, I-J., de Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Kotb, A., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H. K., Das-Gupta, A. and Wolf, J. (2018). Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann. Oncol., 29 (6). S. 1409 - 1417. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Novello, S., Mazieres, J., Oh, I-J., de Castro, J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., Kotb, A., Zeiter, A., Cardona, A., Balas, B., Johannsdottir, H., Das-Gupta, A. and Wolf, J. (2017). Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK plus non-small-cell lung cancer (NSCLC). Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Smeltzer, M., Bunn, B., Choi, Y. S., Coate, L., Corona-Cruz, J., Drilon, A., Duma, N., Edelman, M., Fidler, M. J., Gadgeel, S., Goto, Y., Herbst, R., Hesdorffer, M., Higgins, K., Labdi, B., Leal, T., Liu, S., Mazotti, J., Novello, S., Patel, S., Popat, S., Ramirez, R., Reckamp, K., Reguart, N., Soo, R., Tan, A., Wolf, J., Yano, S., Stiles, B. and Baird, A. (2021). The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers. J. Thorac. Oncol., 16 (10). S. S879 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380
Wolf, J., Helland, A., Oh, I-J, Migliorino, M. R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V and Novello, S. (2022). Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open, 7 (1). AMSTERDAM: ELSEVIER. ISSN 2059-7029
Wolf, J., Oh, I-J., Mazieres, J., de Castro, J., Revil, C., Kotb, A., Johansdottir, H., Zeaiter, A. and Novello, S. (2016). ALUR: a phase 3 study of alectinib versus chemotherapy in previously treated ALK plus non-small cell lung cancer (NSCLC). Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
de Castro, J., Novello, S., Mazieres, J., Oh, I-J., Migliorino, M. R., Helland, A., Dziadziuszko, R., Griesinger, F., de Marinis, F., Zeaiter, A., Cardona, A., Balas, B., Johannsdottir, H., Chlistalla, M., Smoljanovic, V. and Wolf, J. (2017). CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK plus NSCLC. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041